Adherium has announced a strategic partnership with Australian tech company Planet Innovation for device hardware and software development related to Adherium’s inhaler monitoring systems. According to the company, the new deal is “complementary” to the deal with Summatix that was announced in August 2019.
The partnership announcement comes shortly after Adherium announced the appointment of former Vectura CEO James Ward-Lilley as a director and Chairman of the Board and the promotion of Mike Motion to Chief Operating Officer.
Motion commented, “Our partnership with Planet Innovation is a critical step in our revised commercial strategy expanding and enhancing our product portfolio and enables us to access both asthma and COPD with devices facilitating physician reimbursement. This investment reflects the continuing revitalization of Adherium alongside the appointment of a new leadership team, the successful rights issue in January this year and initial commercial partnering agreements such as HGE Health last week.”
Motion added, “Our New Zealand based team has built close links with PI and whilst overseeing the new projects with PI, will also upgrade our existing devices to leverage the new software enabling the physiological data capture required to access the RPM CPT codes. While operating in challenging times due to the COVID-19 pandemic our operational response to the situation, working with our employees and partners, is enabling us to continue activities on the planned timeline. We continue to manage the situation closely in response to new developments.”
Planet Innovation Co-CEO and Co-founder Sam Lanyon said, “Planet Innovation is pleased to be collaborating with Adherium to support their innovation investment in Melbourne as it upgrades its existing software and devices and develops the next set of products with enhanced physiological measurement capabilities.”
Read the Adherium press release.
